Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.

Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, McColm J, Katcherian A, Cueto I, White T, Banerjee S, Hoffman RW.

J Allergy Clin Immunol. 2012 Jul;130(1):145-54.e9. doi: 10.1016/j.jaci.2012.04.024. Epub 2012 Jun 5.

2.

Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.

Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak SJ Jr, Wasfi Y, Wang Y, Szapary P, Krueger JG.

J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. doi: 10.1016/j.jaci.2014.01.025.

3.

IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease.

Friedrich M, Tillack C, Wollenberg A, Schauber J, Brand S.

Inflamm Bowel Dis. 2014 Nov;20(11):1891-901. doi: 10.1097/MIB.0000000000000198.

PMID:
25299544
4.

Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.

Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S.

N Engl J Med. 2012 Mar 29;366(13):1190-9. doi: 10.1056/NEJMoa1109997.

5.

Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.

Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Wetzke M, Maier H, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schauber J, Wollenberg A, Brand S.

Gut. 2014 Apr;63(4):567-77. doi: 10.1136/gutjnl-2012-302853. Epub 2013 Mar 6.

PMID:
23468464
6.

Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo.

Skepner J, Ramesh R, Trocha M, Schmidt D, Baloglu E, Lobera M, Carlson T, Hill J, Orband-Miller LA, Barnes A, Boudjelal M, Sundrud M, Ghosh S, Yang J.

J Immunol. 2014 Mar 15;192(6):2564-75. doi: 10.4049/jimmunol.1302190. Epub 2014 Feb 10.

7.

Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis.

Cheuk S, Wikén M, Blomqvist L, Nylén S, Talme T, Ståhle M, Eidsmo L.

J Immunol. 2014 Apr 1;192(7):3111-20. doi: 10.4049/jimmunol.1302313. Epub 2014 Mar 7.

8.

Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation.

Johnston A, Fritz Y, Dawes SM, Diaconu D, Al-Attar PM, Guzman AM, Chen CS, Fu W, Gudjonsson JE, McCormick TS, Ward NL.

J Immunol. 2013 Mar 1;190(5):2252-62. doi: 10.4049/jimmunol.1201505. Epub 2013 Jan 28.

9.

The role of IL-17 in psoriasis.

Malakouti M, Brown GE, Wang E, Koo J, Levin EC.

J Dermatolog Treat. 2015 Feb;26(1):41-4. doi: 10.3109/09546634.2013.879093. Epub 2014 Feb 20. Review.

PMID:
24552504
10.

Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis.

Singh TP, Schön MP, Wallbrecht K, Gruber-Wackernagel A, Wang XJ, Wolf P.

PLoS One. 2013;8(1):e51752. doi: 10.1371/journal.pone.0051752. Epub 2013 Jan 15.

11.

Ixekizumab for treatment of psoriasis.

Dyring-Andersen B, Skov L, Zachariae C.

Expert Rev Clin Immunol. 2015 Apr;11(4):435-42. doi: 10.1586/1744666X.2015.1023295. Epub 2015 Mar 8. Review.

PMID:
25748485
12.

Interleukin 17A: toward a new understanding of psoriasis pathogenesis.

Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S.

J Am Acad Dermatol. 2014 Jul;71(1):141-50. doi: 10.1016/j.jaad.2013.12.036. Epub 2014 Mar 18. Review.

PMID:
24655820
13.

Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway.

Balato A, Schiattarella M, Di Caprio R, Lembo S, Mattii M, Balato N, Ayala F.

J Eur Acad Dermatol Venereol. 2014 Aug;28(8):1016-24. doi: 10.1111/jdv.12240. Epub 2013 Sep 4.

PMID:
24033358
14.

Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.

Blauvelt A.

Expert Opin Biol Ther. 2016;16(2):255-63. doi: 10.1517/14712598.2016.1132695. Epub 2016 Jan 25. Review.

PMID:
26666707
15.

Therapeutic implications of IL-17A blockade in psoriasis.

Puig L, Carrascosa JM.

Actas Dermosifiliogr. 2014 Oct;105 Suppl 1:1-5. doi: 10.1016/S0001-7310(14)70012-2. No abstract available.

PMID:
25398486
16.

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.

Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M.

J Am Acad Dermatol. 2014 Dec;71(6):1176-82. doi: 10.1016/j.jaad.2014.07.048. Epub 2014 Sep 19.

PMID:
25242558
17.

Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells.

Ma HL, Napierata L, Stedman N, Benoit S, Collins M, Nickerson-Nutter C, Young DA.

Arthritis Rheum. 2010 Feb;62(2):430-40. doi: 10.1002/art.27203.

18.

Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.

Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC.

Exp Dermatol. 2015 Jul;24(7):529-35. doi: 10.1111/exd.12710. Epub 2015 May 8.

19.

Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab.

Bissonnette R, Langley RG, Papp K, Matheson R, Toth D, Hultquist M, Geba GP, White B.

Arch Dermatol Res. 2009 Jul;301(6):429-42. doi: 10.1007/s00403-009-0961-7. Epub 2009 May 27.

PMID:
19471949
20.

GILZ regulates Th17 responses and restrains IL-17-mediated skin inflammation.

Jones SA, Perera DN, Fan H, Russ BE, Harris J, Morand EF.

J Autoimmun. 2015 Jul;61:73-80. doi: 10.1016/j.jaut.2015.05.010. Epub 2015 Jun 13.

PMID:
26077873

Supplemental Content

Support Center